The contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.
This phase 1 study assessed BGB-16673, an investigational drug that degrades the BTK protein, in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had received multiple prior therapies. Among 66 patients, 86% responded to treatment, including those with high-risk genetic mutations and prior resistance to BTK inhibitors. BGB-16673 has a tolerable safety profile. Treatment-emergent adverse events (TEAEs) of any grade occurring in ≥25% of patients were fatigue, contusion/bruising, diarrhea, and neutropenia. Grade ≥3 TEAEs occurred in 63% of patients. Four patients had TEAEs that led to death (all due to infections), but no deaths were related to treatment. BGB-16673 showed robust and deepening responses, and further studies are ongoing to confirm the potential benefits.
